Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'er Zhike Tangjiang is an over-the-counter (OTC) pediatric cough syrup developed and marketed by Ginwa Enterprise. It is a combination pharmaceutical product formulated according to standard Chinese pharmacopoeia specifications, typically containing ammonium chloride, glycyrrhiza liquid extract, platycodon liquid extract, and orange peel tincture. The syrup functions as both an expectorant and a demulcent; ammonium chloride and the saponins in platycodon act by irritating the gastric mucosa to reflexively stimulate the secretion of respiratory tract fluids, which helps to liquefy and loosen phlegm. Glycyrrhiza provides a soothing effect on the respiratory mucosa, acting as a mild antitussive. It is primarily indicated for the treatment of cough and the promotion of expectoration in children suffering from colds or bronchitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiao'er Zhike Tangjiang.